GSK gets FDA approval for new severe asthma drug

GSK's Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK's own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen.

Editor's Pick

Top Story GSK Gets FDA Approval for New Severe Asthma Drug With a Dosing Advantage GSK's Exdensur requires just two injections a year to treat severe asthma. Less frequent injections give this new biologic medicine a dosing edge over one of GSK's own blockbuster respiratory products as well as severe asthma drugs from companies such as AstraZeneca, Sanofi, and Amgen. Sponsored Helping to Transform Healthcare with Transparent Data Insights Presented by Claritev Claritev helps make healthcare clearer, smarter, and more affordable. With 40+ years of claims repricing expertise and powerful AI technology, we turn complex data into actionable insights. Our enterprise platform drives price transparency, optimizes networks, and reshapes benefit plan design—helping payers, providers, and employers deliver real value in healthcare.  Learn more

Featured News

Teal Health Teams Up With Thatch to Expand Access to Cervical Cancer Screening Through a new partnership, Thatch's employer customers can now offer Teal Health's at-home cervical cancer screening as an employee benefit through an ICHRA. When Inaction Becomes Negligence in the Age of AI We are on the cusp of being held accountable not just for what we did wrong, but for what we failed to do, especially when readily available, life-saving technology could have made a difference. Beyond the Numbers: Every Data Point Tells a Different Story While data and cost are important elements in recognizing issues, the measure of success isn't just about the data or the numbers; it's about ensuring that older adults can manage and maintain their expectations about health and aging in place.

Video   How Merck Views AI Asheesh Chhabra, VP & Chief Data Officer of Merck, shares how they are viewing AI.

Sponsored As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities Presented by Munich Re Specialty – North America In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play. Learn More

Resources

Debunked Episode 21: The Drug Price Debate, AI in Healthcare Companies Face Consolidation But How Much? How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are working with the Trump administration to lower costs? View Now

MedCity News • PO Box 901 • New York, NY unsubscribe